Epidyolex Unión Europea - lituano - EMA (European Medicines Agency)

epidyolex

jazz pharmaceuticals ireland limited - cannabidiol - lennox gastaut syndrome; epilepsies, myoclonic - antiepileptics, - epidyolex yra nurodyta naudoti kaip adjunctive terapijos priepuolių, susijusių su lennox gastaut sindromas (lgs) arba dravet sindromas (ds), kartu su klobazamas, pacientams, 2 metų amžiaus ir vyresni.

Roctavian Unión Europea - lituano - EMA (European Medicines Agency)

roctavian

biomarin international limited - valoctocogene roxaparvovec - antihemoraginiai - treatment of severe haemophilia a (congenital factor viii deficiency) in adult patients without a history of factor viii inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (aav5).

Kauliv Unión Europea - lituano - EMA (European Medicines Agency)

kauliv

strides pharma (cyprus) limited - teriparatide - osteoporosis; osteoporosis, postmenopausal - kalcio homeostazė - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Unión Europea - lituano - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogrelio besilatas - peripheral vascular diseases; stroke; myocardial infarction - antitromboziniai vaistai - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segmento pakilimu ūmus miokardo infarktas, kartu su asr medikamentais gydytų pacientų, atitinkančių trombolizinė terapija. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. daugiau informacijos, skaitykite skyrių 5.

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Unión Europea - lituano - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrelio hidrochloridas - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitromboziniai vaistai - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Copalia HCT Unión Europea - lituano - EMA (European Medicines Agency)

copalia hct

novartis europharm limited - amlodipine, valsartan, hydrochlorothiazide - hipertenzija - angiotenzino ii antagonistai, deriniai, agentai, veikiantys renino-angiotenzino sistemą, angiotenzino ii antagonistai ir kalcio kanalų blokatoriai. - pirminės arterinės hipertenzijos gydymas kaip pakaitinė terapija suaugusiems pacientams, kurių kraujospūdžio tinkamai kontroliuojama į derinį amlodipino, valsartano ir hidrochlorotiazido (hct), paimti tris vienkomponenčiai preparatai arba kartu su šiuolaikiška dviejų ir vieno komponento sudėties.

Dafiro HCT Unión Europea - lituano - EMA (European Medicines Agency)

dafiro hct

novartis europharm limited - valsartan, hydrochlorothiazide, amlodipine besilate - hipertenzija - renino ir angiotenzino sistemos veikiantys vaistai - pirminės arterinės hipertenzijos gydymas kaip pakaitinė terapija suaugusiems pacientams, kurių kraujospūdžio tinkamai kontroliuojama į derinį amlodipino, valsartano ir hidrochlorotiazido (hct), paimti tris vienkomponenčiai preparatai arba kartu su šiuolaikiška dviejų ir vieno komponento sudėties.

Exforge HCT Unión Europea - lituano - EMA (European Medicines Agency)

exforge hct

novartis europharm limited - valsartan, hydrochlorothiazide, amlodipine besilate - hipertenzija - renino ir angiotenzino sistemos veikiantys vaistai - pirminės arterinės hipertenzijos gydymas kaip pakaitinė terapija suaugusiems pacientams, kurių kraujospūdžio tinkamai kontroliuojama į derinį amlodipino, valsartano ir hidrochlorotiazido (hct), paimti tris vienkomponenčiai preparatai arba kartu su šiuolaikiška dviejų ir vieno komponento sudėties.

Taltz Unión Europea - lituano - EMA (European Medicines Agency)

taltz

eli lilly and company (ireland) limited - iksekizumabas - psoriazė - imunosupresantai - apnašas psoriasistaltz fluorouracilu gydyti vidutinio sunkumo ar sunkia plokštelinės psoriazės suaugusiems, kurie yra kandidatai sisteminės terapijos. psoriazinis arthritistaltz, atskirai arba kartu su metotreksatu, fluorouracilu ir folino aktyvių psoriaziniu artritu suaugusių pacientų, kurie reagavo netinkamai, arba kurie netoleruoja vieno ar daugiau ligų-pakeisti anti-reumato narkotikų (dmard) terapija.

Dasatinib Viatris [Dasatinib Mylan] Lituania - lituano - SMCA (Valstybinė vaistų kontrolės tarnyba)

dasatinib viatris [dasatinib mylan]

viatris limited - dazatinibas - plėvele dengtos tabletės - 50 mg - dasatinib